Table 3.
Association between genetic polymorphisms and prostate cancer risk among cases and controls.
| Gene | Polymorphism | Genotype | Case versus control | ||
|---|---|---|---|---|---|
| OR | 95% CI | P value | |||
| SRD5A2 | A49T | A/A | Reference | ||
| A/T | 0.97 | 0.56–1.67 | 1 | ||
| T/T | 0.40 | 0.31–0.52 | 0.000 | ||
| A/T + T/T | 1.31 | 0.77–2.22 | 0.394 | ||
| V89L | V/V | Reference | |||
| V/L | 0.34 | 0.19–0.61 | |||
| L/L | 0.06 | 0.02–0.20 | |||
| V/L + L/L | 0.27 | 0.15–0.48 | 0.000 | ||
|
| |||||
| MTHFR | C677T | C/C | Reference | ||
| C/T | 2.22 | 1.26–3.92 | 0.008 | ||
| T/T | 1.73 | 0.11–28.73 | 1 | ||
| C/T + T/T | 2.21 | 1.26–3.89 | 0.008 | ||
|
| |||||
| AR | CAG repeats | ≥22 CAGs | Reference | ||
| ≤21 CAGs | 2.99 | 1.79–5.01 | 0.000 | ||
OR, odds ratio.